Vasostatin-2 inhibits cell proliferation and adhesion in vascular smooth muscle cells, which are associated with the progression of atherosclerosis

Biochemical and Biophysical Research Communications

Volumn 469, Issue 4, 2016, Pages 948-953

  Hou, Jianghong ^a   Xue, Xiaolin ^b   Li, Junnong ^a  

^a Central Hospital of Weinan City   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Atherosclerosis; Inflammation; Proliferation; Vasostatin 2; VSMCs

Indexed keywords

C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MESSENGER RNA; PROTEIN; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; SOLUBLE VASCULAR CELL ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASOSTATIN 2; CELL ADHESION MOLECULE; CHROMOGRANIN A; PEPTIDE FRAGMENT; VASOSTATIN II;

ADULT; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DOWN REGULATION; ECTOPIC EXPRESSION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MTT ASSAY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR SMOOTH MUSCLE CELL; WESTERN BLOTTING; CELL CULTURE; DOSE RESPONSE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

ATHEROSCLEROSIS; CELL ADHESION; CELL ADHESION MOLECULES; CELL PROLIFERATION; CELLS, CULTURED; CHROMOGRANIN A; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PEPTIDE FRAGMENTS;

EID: 84957438323     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.12.097     Document Type: Article

References (28)

1. A.J. Lusis, R. Mar, and P. Pajukanta Genetics of atherosclerosis Annu. Rev. Genomics Hum. Genet. 5 2004 189 218
2. C.K. Glass, and J.L. Witztum Atherosclerosis: the road ahead Cell 104 2001 503 516
3. P. Libby Inflammation in Atherosclerosis Nature 420 2002 868 874
4. M.C. Clarke, N. Figg, J.J. Maguire, A.P. Davenport, M. Goddard, T.D. Littlewood, and M.R. Bennett Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis Nat. Med. 12 2006 1075 1080
5. L. Taupenot, K.L. Harper, and D.T. O'Connor The chromogranin-secretogranin family N. Engl. J. Med. 348 2003 1134 1149
6. B. Tota, M.C. Cerra, and A. Gattuso Catecholamines, cardiac natriuretic peptides and chromogranin A: evolution and physiopathology of a 'whip-brake'system of the endocrine heart J. Exp. Biol. 213 2010 3081 3103
7. L. Lu, Y.N. Wang, M.C. Li, H.B. Wang, L.J. Pu, W.Q. Niu, H. Meng, E.L. Yang, R.Y. Zhang, and Q. Zhang Reduced serum levels of vasostatin-2, an anti-inflammatory peptide derived from chromogranin A, are associated with the presence and severity of coronary artery disease Eur. heart J. 33 2012 2297 2306
8. S. Capellino, T. Lowin, P. Angele, W. Falk, J. Grifka, and R.H. Straub Increased chromogranin A levels indicate sympathetic hyperactivity in patients with rheumatoid arthritis and systemic lupus erythematosus J. Rheumatol. 35 2008 91 99
9. M. Cerra, M. Gallo, T. Angelone, A. Quintieri, E. Pulerà, E. Filice, B. Guérold, P. Shooshtarizadeh, R. Levi, and R. Ramella The homologous rat chromogranin A1-64 (rCGA1-64) modulates myocardial and coronary function in rat heart to counteract adrenergic stimulation indirectly via endothelium-derived nitric oxide FASEB J. 22 2008 3992 4004
10. A. Blois, B. Srebro, M. Mandalà, A. Corti, K.B. Helle, and G. Serck-Hanssen The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells Regul. Pept. 135 2006 78 84
11. E. Ferrero, S. Scabini, E. Magni, C. Foglieni, D. Belloni, B. Colombo, F. Curnis, A. Villa, M.E. Ferrero, and A. Corti Chromogranin A protects vessels against tumor necrosis factor α-induced vascular leakage FASEB J. 18 2004 554 556
12. R. Huegel, P. Velasco, M.D.L.L. Sierra, E. Christophers, J.M. Schröder, T. Schwarz, G. Tosato, and B. Lange-Asschenfeldt Novel anti-inflammatory properties of the angiogenesis inhibitor vasostatin J. Investig. Dermatol. 127 2007 65 74
13. D. Versari, E. Daghini, A. Virdis, L. Ghiadoni, and S. Taddei Endothelial dysfunction as a target for prevention of cardiovascular disease Diabetes Care 32 2009 S314 S321
14. U. Förstermann, and T. Münzel Endothelial nitric oxide synthase in vascular disease from marvel to menace Circulation 113 2006 1708 1714
15. M. Navab, G. Anantharamaiah, S.T. Reddy, B.J. Van Lenten, and A.M. Fogelman HDL as a biomarker, potential therapeutic target, and therapy Diabetes 58 2009 2711 2717
16. D.P. Bartel MicroRNAs: genomics, biogenesis, mechanism, and function Cell 116 2004 281 297
17. L. Zhang, X. Liu, H. Jin, X. Guo, L. Xia, Z. Chen, M. Bai, J. Liu, X. Shang, K. Wu, Y. Pan, and D. Fan miR-206 inhibits gastric cancer proliferation in part by repressing cyclinD2 Cancer Lett. 332 2013 94 101
18. D. Béchard, A. Scherpereel, H. Hammad, T. Gentina, A. Tsicopoulos, M. Aumercier, J. Pestel, J.-P. Dessaint, A.-B. Tonnel, and P. Lassalle Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1 J. Immunol. 167 2001 3099 3106
19. A.H. Sprague, and R.A. Khalil Inflammatory cytokines in vascular dysfunction and vascular disease Biochem. Pharmacol. 78 2009 539 552
20. L. Jing, J.-Z. Zhang, L. Zhao, Y.-L. Wang, and F.-Y. Guo High-expression of transforming growth factor β1 and phosphorylation of extracellular signal-regulated protein kinase in vascular smooth muscle cells from aorta and renal arterioles of spontaneous hypertension rats Clin. Exp. Hypertens. 29 2007 107 117
21. G. Di Comite, and A. Morganti Chromogranin A: a novel factor acting at the cross road between the neuroendocrine and the cardiovascular systems J. Hypertens. 29 2011 409 414
22. B. Tota, T. Angelone, R. Mazza, and M. Cerra The chromogranin A-derived vasostatins: new players in the endocrine heart Curr. Med. Chem. 15 2008 1444 1451
23. J.-J. Li, and C.-H. Fang C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases Med. Hypotheses 62 2004 499 506
24. P.M. Ridker High-sensitivity C-reactive protein potential adjunct for global risk assessment in the primary prevention of cardiovascular disease Circulation 103 2001 1813 1818
25. C. Popa, M.G. Netea, P.L. Van Riel, J.W. van der Meer, and A.F. Stalenhoef The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk J. Lipid Res. 48 2007 751 762
26. W. Van Leeuwen, M. Lehto, P. Karisola, H. Lindholm, R. Luukkonen, M. Sallinen, M. Härmä, T. Porkka-Heiskanen, and H. Alenius Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP PloS one 4 2009 e4589
27. M.I. Cybulsky, K. Iiyama, H. Li, S. Zhu, M. Chen, M. Iiyama, V. Davis, J.-C. Gutierrez-Ramos, P.W. Connelly, and D.S. Milstone A major role for VCAM-1, but not ICAM-1, in early atherosclerosis J. Clin. Investig. 107 2001 1255
28. L. Quagliaro, L. Piconi, R. Assaloni, R. Da Ros, A. Maier, G. Zuodar, and A. Ceriello Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production Atherosclerosis 183 2005 259 267